BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4875710)

  • 1. Insulin secretory blockade by benzothiadiazines and catecholamines: reversal by sulfonylureas.
    Seltzer HS; Crout JR
    Ann N Y Acad Sci; 1968 Apr; 150(2):309-21. PubMed ID: 4875710
    [No Abstract]   [Full Text] [Related]  

  • 2. The action of diazoxide on insulin secretion, medullo-adrenal secretion, and the liberation of catecholamines.
    Loubatières A; Mariani MM; Alric R
    Ann N Y Acad Sci; 1968 Apr; 150(2):226-41. PubMed ID: 4875709
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the mechanism of xylitol-induced insulin secretion in dogs. Effect of its infusion into the pancreatic artery, and the inhibition by epinephrine and diazoxide of xylitol-induced hyperinsulinaemia.
    Kuzuya T; Kanazawa Y
    Diabetologia; 1969 Aug; 5(4):248-57. PubMed ID: 4902720
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
    Loubatiéres A; Mariani MM
    Actual Physiol Pathol (Paris); 1973; 4():237-66. PubMed ID: 4219256
    [No Abstract]   [Full Text] [Related]  

  • 5. AO44: an improved hyperglycemic agent.
    Lopez N; Basabe J; Grant A; Krees S; Terry M; Viktora J; Wolff F
    Metabolism; 1971 Apr; 20(4):373-83. PubMed ID: 5550304
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of thiazides upon insulin secretion in vitro.
    Malaisse W; Malaisse-Legae F
    Arch Int Pharmacodyn Ther; 1968 Jan; 171(1):235-9. PubMed ID: 4868989
    [No Abstract]   [Full Text] [Related]  

  • 7. [Insulin secretion in vitro. II. Inhibition of glucose induced insulin release by diazoxide].
    Frerichs H; Gerber R; Creutzfeldt W
    Diabetologia; 1966 Dec; 2(4):269-76. PubMed ID: 4902707
    [No Abstract]   [Full Text] [Related]  

  • 8. The morphological substrate of the inhibition of insulin secretion by diazoxide.
    Creutzfeldt W; Creutzfeldt C; Frerichs H; Perings E; Sicklinger K
    Horm Metab Res; 1969 Mar; 1(2):53-64. PubMed ID: 4334867
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Alric R; Chapal J
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1354-63. PubMed ID: 4899083
    [No Abstract]   [Full Text] [Related]  

  • 11. Mode of action of a diazoxide analog (A025). Its effects on insulin secretion.
    Grant AM; Basabe JC; Lopez NL; Krees SV; Wolff FW
    Diabetes; 1970 Sep; 19(9):630-8. PubMed ID: 4990295
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of diazoxide on glucagon-induced insulin secretion].
    Brech WJ; Kaess H; Schlierf G; Rohs M
    Klin Wochenschr; 1968 Apr; 46(8):449-50. PubMed ID: 4879594
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells.
    Mariot P; Gilon P; Nenquin M; Henquin JC
    Diabetes; 1998 Mar; 47(3):365-73. PubMed ID: 9519741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the effect of various sulfonylureas during adrenergic blockade of the insulin secretion in man].
    Haslbeck M; Brauch K; Hepp KD; Mehnert H
    Verh Dtsch Ges Inn Med; 1971; 77():543-6. PubMed ID: 5005529
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperresponsiveness to tolbutamide of dogs pretreated with diazoxide.
    Anderson JH; Byrd GW; Blackard WG
    Metabolism; 1971 Nov; 20(11):1023-30. PubMed ID: 4329940
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors controlling release of insulin from beta cell in relation to diabetes mellitus.
    Romanoff NE
    N Y State J Med; 1968 Feb; 68(3):385-91. PubMed ID: 4865846
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental study of a new especially active hypoglycemic sulfonamide, HB-419 or Glibenclamide].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Chapal J
    Diabetologia; 1969 Feb; 5(1):1-10. PubMed ID: 4907149
    [No Abstract]   [Full Text] [Related]  

  • 18. [Morphology and histochemistry of insulin secretion].
    Creutzfelt W
    Acta Diabetol Lat; 1968 Oct; 5 Suppl 1():387-416. PubMed ID: 4313827
    [No Abstract]   [Full Text] [Related]  

  • 19. Experimental and clinical studies with diazoxide.
    Wolff F; Hirsch E; Wales J; Viktora J
    Ann N Y Acad Sci; 1968 Apr; 150(2):429-41. PubMed ID: 4875711
    [No Abstract]   [Full Text] [Related]  

  • 20. Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man.
    Fajans SS; Floyd JC; Thiffault CA; Knopf RF; Harrison TS; Conn JW
    Ann N Y Acad Sci; 1968 Apr; 150(2):261-80. PubMed ID: 4299219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.